SRC and breast carcinoma: In breast cancers, LEG1 activates the downstream focal adhesion kinase/c‐Src pathway, which further stimulates ERK and STAT3 signalling leading to enhanced expression of survivin, and inhibits apoptosis and conferred drug resistance [30].